Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and
bleeding from the lining of the rectum and colon (large intestine). This study will assess
how safe and effective Upadacitinib is in treating pediatric participants with UC....
Age: 2 - 17 years
Gender: All
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the
drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Age: 2 - 17 years
Gender: All
ABTECT - Maintenance
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of
ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with
moderately to severely active ulcerative colitis who have inadequate response, no respo...
Age: 16 years - 66+
Gender: All
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and
safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with
moderately to severely active ulcerative colitis who have inadequate response, no respon...
Age: 16 years - 66+
Gender: All
A Long-term Extension Study of Ustekinumab in Pediatric Participants
The purpose of this study is to collect long-term safety data of subcutaneous (SC)
ustekinumab
Age: 2 - 17 years
Gender: All
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in
pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will
last about 172 weeks and may include up to 44 visits.
Age: 2 - 19 years
Gender: All
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK)
of tofacitinib in pediatric participants with moderately to severely active UC. In the US and
EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of...
Age: 2 - 17 years
Gender: All
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as
maintenance therapy in participants who completed prior 12-week induction study AMAN
(NCT03518086).
Age: 18 - 80 years
Gender: All
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients
(age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical
practice. TARGET-IBD will create a research registry of patients with IBD within academic...
Age: 2 years - 66+
Gender: All
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in
patients with moderately to severely active UC who are treated as recommended in the product
label.
Age: 18 - 99 years
Gender: All